According to Frost & Sullivan, the global biopharmaceutical market size has reached $341.
2 billion in 2021 and is expected to grow to $665.
1 billion by 2030, with a CAGR (2022E-2030E) of 7.
6%.
Domestically, China's biopharmaceutical market reached RMB464.
4 billion in 2021 and is expected to grow to RMB1,319.
8 billion by 2030, with a CAGR (2022E-2030E) of 11.
6%.
To achieve import substitution of biopharmaceutical equipment, it is necessary to promote development with quality and innovation (Image source: Pharmaceutical Network)
At present, the development of the biopharmaceutical industry is clearly thriving
.
The industry believes that in this context, it will continue to open the growth ceiling
of domestic equipment consumables enterprises.
It is reported that the upstream industry chain of biopharmaceuticals mainly includes raw materials, consumables and instruments/equipment
.
At present, reagents and consumables have basically been localized in China, and are still making continuous progress
in benchmarking against the international standard.
Such as Navitas, Boglon in the field of chromatography packing materials/chromatography media; Single-use bioreactors, Lepure Biologics in the field of reaction/storage/stirring bags, Dongfulong; Opmeis in the field of culture media, etc
.
In the future, under the background of the rapid development of the biomedical industry, the industry generally believes that the localization of domestic biopharmaceutical equipment and consumables and the controllable supply chain will be increasingly accelerated
.
In fact, the domestic biopharmaceutical industry chain, especially the upstream subdivisions, has experienced the process
from 0 to 1 and from 1 to 10.
In the upstream subdivisions, a number of excellent companies have been run, and the individual product and service capabilities can already be benchmarked against international giants, and the industrial chain aggregation effect has initially appeared
.
For example, Chutian Technology mentioned in an institutional survey on August 28 that the company achieved good results in the first half of 2022, one of the major reasons being high-end import substitution
.
Among them, Chutian Technology has made rapid progress in the front-end process and equipment layout of biopharmaceuticals, and in 2021, Chutian Youster and Chutian Microspheres have been established successively, which are respectively used in the production and sales of related single-use process equipment, consumables and software in the field of biopharmaceuticals, as well as the development and production
of biopharmaceutical process products such as disposable bioreactors, liquid preparation bags, storage bags and their membranes.
In addition, at the end of February this year, Chutian Technology announced the establishment of a holding company, Chutiansi Weikang Gene, which is committed to promoting the layout
in the field of biotechnology.
In addition, Dongfulong announced that it will "hold hands" with Tianjin Jieke, and the two parties will reach cooperation
in various fields such as upstream and downstream processes of biological drugs, GMP production line equipment, core consumables, plant construction, and future factory digitalization and automation.
It is reported that Dongfulong started with freeze-drying, in recent years, the company has fully laid out the upstream and downstream fields of biopharmaceuticals, and the process has always run through the whole process, providing overall solutions
for process research, core equipment, consumables and system engineering.
At present, from the direction of the layout of many pharmaceutical enterprises, the pace of domestic substitution in biological equipment is accelerating
.
It is worth noting that the industry believes that compared with international enterprises, quality stability and innovation are still the main challenges facing the biopharmaceutical consumables and equipment industry, and breaking through this problem requires efforts in the level of automation
.
Therefore, the industry also recommends that enterprises continue to invest in automated and intelligent production line equipment in the process of becoming bigger and stronger, and further improve the technical level of products, so as to cut into the pharmaceutical industry chain in multiple links in the future and achieve import substitution
in an all-round and multi-field manner.
={"common":{"bdSnsKey":{},"bdText":"","bdMini":"1","bdMiniList":false,"bdPic":"","bdStyle":"0","bdSize":"32"},"share":{},"image":{"viewList":[" weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"],"viewText":"share:","viewSize":"24"},"selectShare":{" bdContainerClass":null,"bdSelectMiniList":["weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"]}}; with(document)0[(getElementsByTagName('head')[0]|| body).
appendChild(createElement('script')).
src='http://bdimg.
share.
baidu.
com/static/api/js/share.
js?v=89860593.
js?cdnversion='+~(-new Date()/36e5)]; 
